25 May

Supreme Court double patenting decision worth $40 billion to Amgen

The Supreme Court’s decision not to intervene in Sandoz v Immunex leaves concerns over double patenting gamesmanship unaddressed and gives Amgen subsidiary a clear path to almost a decade’s more exclusivity

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth